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Introduction
Acute graft-versus-host disease (GVHD), induced by donor T cells 
that recognize host alloantigenic disparities, is a significant cause 
of morbidity and mortality following allogeneic bone marrow 
transplantation (BMT) (1, 2). Current approaches to prevent or 
treat GVHD focus on blocking T cell activation or the proinflam-
matory products of activated T cells using immunosuppressive 
drugs such as calcineurin inhibitors, mycophenolate mofetil, and 
corticosteroids. Many new drugs in various stages of development 
aim to more specifically target selective T cell functions or acti-
vated T cells (3), including agents designed to block T cell costim-
ulatory pathways such as CD28, CD154, and ICOS.
Programmed death-1 (PD-1) is an inhibitory receptor that 
attenuates T cell activation by recruitment of phosphatases, which 
negatively regulate T cell receptor (TCR) signaling (4, 5). While 
PD-1 expression is low in resting T cells, it is inducible following 
T cell activation, and is also found on activated B cells, NKT cells, 
and activated monocytes (6). The importance of this molecule in 
restraining immune responses has been made readily apparent by 
numerous studies that show that blockade of PD-1 provides effec-
tive immune stimulation against tumors (7–10).
Programmed death ligand-1 (PD-L1) interaction with PD-1 induces T cell exhaustion and is a therapeutic target to enhance 
immune responses against cancer and chronic infections. In murine bone marrow transplant models, PD-L1 expression 
on host target tissues reduces the incidence of graft-versus-host disease (GVHD). PD-L1 is also expressed on T cells; 
however, it is unclear whether PD-L1 on this population influences immune function. Here, we examined the effects of 
PD-L1 modulation of T cell function in GVHD. In patients with severe GVHD, PD-L1 expression was increased on donor T 
cells. Compared with mice that received WT T cells, GVHD was reduced in animals that received T cells from Pdl1–/– donors. 
PD-L1–deficient T cells had reduced expression of gut homing receptors, diminished production of inflammatory cytokines, 
and enhanced rates of apoptosis. Moreover, multiple bioenergetic pathways, including aerobic glycolysis, oxidative 
phosphorylation, and fatty acid metabolism, were also reduced in T cells lacking PD-L1. Finally, the reduction of acute GVHD 
lethality in mice that received Pdl1–/– donor cells did not affect graft-versus-leukemia responses. These data demonstrate 
that PD-L1 selectively enhances T cell–mediated immune responses, suggesting a context-dependent function of the PD-1/
PD-L1 axis, and suggest selective inhibition of PD-L1 on donor T cells as a potential strategy to prevent or ameliorate GVHD.
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phages (14, 15). PD-L1 is constitutively expressed at low levels and 
induced by IFNs, whereas PD-L2 is induced primarily by GM-CSF 
and IL-4 (14). This broad expression of PD-L1 suggests that PD-L1 
may regulate self-reactive T or B cells and inflammatory responses 
PD-1 has 2 identified ligands, PD-L1 and PD-L2, which dif-
fer in their expression patterns, as PD-L1 is expressed on both 
hematopoietic and nonhematopoietic cells (11–14), whereas 
PD-L2 expression is restricted primarily to DCs and macro-
Figure 1. GVHD-induced PD-L1 upregulation on donor Teffs contributes to lethality. (A and B) Lethally irradiated B6 or BALB/c recipients were infused with 
107 WT B6 BM cells plus 6 × 106 B6 Ly5.2 (CD45.1+) splenocytes. Mice were sacrificed on day 5 after BMT (n = 5 per group), and splenic donor CD4 and CD8 T 
cells were analyzed by flow cytometry for PD-1 (A) or PD-L1 (B) expression. Splenocytes of naive B6 Ly5.2 mice (n = 5) were included in the analysis. (C) T cells 
isolated from normal human donors (n = 3) were stimulated with anti–CD3/CD28 beads, and CD4 and CD8 T cells were stained for PD-L1 expression every 24 
hours after stimulation. (A–C) Data are representative of 2 independent experiments. (D) Human PBMCs were collected from healthy volunteers and from 
patients after allogeneic BMT with or without GVHD at the time of collection (Supplemental Table 1). CD4 and CD8 T cells were then stained and analyzed for 
PD-L1 expression using the gating strategy as shown in Supplemental Figure 2A. (E) Lethally irradiated BALB/c recipients were infused with 107 WT B6 BM 
cells alone or with 1 × 106 WT B6 or Pdl1–/– purified T cells. Kaplan-Meier survival plot represents pooled data from 4 independent experiments (n = 31–34 per 
group; recipients of WT vs. Pdl1–/– donor T cells, P < 0.0001). (F) Lethally irradiated B10.BR recipients were infused with 107 WT B6 BM cells alone or with 3 × 
106 WT B6 or Pdl1–/– purified T cells. Kaplan-Meier survival plot represents pooled data from 2 independent experiments (n = 16–20 per group; recipients of 
WT vs. Pdl1–/– donor T cells, P = 0.0047). (G) Lethally irradiated BALB/c recipients were infused with 107 WT B6 BM cells alone or with 1 × 106 WT B6, Pdl1–/–, or 
Pdl1–/– Pdl2–/– purified T cells. Kaplan-Meier survival plot of transplanted mice is shown (n = 8 per group; recipients of WT vs. Pdl1–/– donor T cells, P = 0.006; 
recipients of WT vs. Pdl1–/– Pdl2–/– donor T cells, P = 0.011). Data represent mean ± SEM (A, B, and D), and P values were calculated by 2-tailed t test (A, B, and 
D) or log-rank test (E–G). *P < 0.05, ***P < 0.001.
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and CD8 T cells with peak expression on day 2 and then gradual 
diminishing (Figure 1C). To determine whether GVHD patients 
had increased PD-L1 expression, human PBMCs were collected 
from healthy volunteers and from patients after allogeneic BMT 
without GVHD or at the time of GVHD diagnosis (Supplemental 
Table 1). We observed a significant increase in PD-L1 expression 
on both CD4 and CD8 T cells in GVHD patients, whereas no sig-
nificant difference was detected in patients with no GVHD versus 
healthy controls (Figure 1D and Supplemental Figure 2).
Given its coinhibitory activity when PD-L1 is expressed on 
host parenchymal cells during GVHD (22), we postulated that 
PD-L1 expression on activated donor T cells would inhibit GVHD 
by downregulating donor antihost T cell responses through T 
cell–T cell interactions. Surprisingly, however, T cell–mediated 
GVHD lethality and clinical scores were markedly ameliorated in 
recipients of Pdl1–/– donor T cells (Figure 1E and Supplemental Fig-
ure 3, A and B). These findings were replicated in a second model 
(B6→B10.BR), where again GVHD was much milder when donor 
T cells were PD-L1 deficient (Figure 1F and Supplemental Figure 
3C). Finally, concomitant PD-L2 deficiency did not alter lethality 
in BALB/c recipients of Pdl1–/– versus Pdl1–/– Pdl2–/– donor T cells at 
doses of 1 × 106 (Figure 1G) or 2 × 106 (P0.417, data not shown) 
cells, indicating that, in contrast to its inhibitory effect on host par-
enchymal cells, PD-L1 but not PD-L2 functions in donor T cells to 
augment GVHD lethality.
Decreased gut homing and cytokine production by Pdl1–/– donor T 
cells. As the gut is a primary GVHD target organ, we analyzed the 
expression of gut adhesion and chemokine homing receptors (25, 
26) as well as cell activation markers. We found that Pdl1–/– donor 
T cells had decreased expression of selected activation markers 
(CD25, CD44, and lysosomal marker CD107a) and higher lev-
els of CD62L expression (Figure 2A and data not shown). Pdl1–/– 
donor T cells had decreased expression in gut homing receptors 
as denoted by LPAM-1 (α4β7), CCR9, and CXCR3 compared with 
WT donor T cells (Figure 2, B–E), and the percentage and abso-
lute numbers of Pdl1–/– donor T cells expressing IFN-γ, TNF-α, 
IFN-γ/TNF-α, IL-6, or IL-17 were significantly reduced on day 7 
after BMT (Figure 2, F–I, and data not shown). Consistent with the 
reduced activation and cytokine expression data, histologic anal-
ysis on day 24 showed a reduction in the damage to the colon and 
ileum in recipients of Pdl1–/– donor T cells (Figure 3A). This was 
associated with a reduction in absolute numbers and proliferation 
of donor T cells (Figure 3B), and expression of proinflammatory 
cytokines (Figure 3, C–F) by lamina propria lymphocytes isolated 
from colon (Figure 3, B–F) and small intestine (data not shown). 
Finally, we measured epithelial integrity of the gastrointestinal 
tract by oral administration of FITC-dextran, which enters into 
the bloodstream if the epithelial barrier has been compromised 
(27). As expected given a reduction in histologic scores, we found 
better-preserved epithelial integrity as well in recipients of Pdl1–/– 
compared with WT donor T cells (Figure 3G).
Decreased Teff function is central to reduced GVHD with Pdl1–/– 
donor T cells. Tregs are able to modulate GVHD severity and 
lethality (28, 29), leading us to ask whether PD-L1 deficiency on 
donor T cells was acting to lessen disease via effects on Tregs. We 
found that WT Tregs activated in vitro had elevated expression of 
PD-1 and PD-L1 but not PD-L2 as compared with resting T cells 
in nonlymphoid as well as lymphoid organs. Further complexity 
is added to the system by the fact that PD-L1 has a second ligand, 
namely B7-1 (CD80) (16).
The specific inhibitory role of PD-L1 in multiple types of 
immune responses is well established (17–22). In the specific case 
of BMT, PD-L1 expressed by recipient hematopoietic and par-
enchymal cells induces alloreactive CD8 T cell dysfunction and 
restrains graft-versus-leukemia effects (23, 24). These studies have 
all focused on the role of PD-L1 on non-T cells in restraining T cell 
responses. However, while, as noted above, PD-L1 is expressed as 
well on T cells themselves, its function on T cells during physiologic 
in vivo immune responses is not known. To address this issue, we 
investigated the role of PD-L1 expressed by donor T cells in a model 
of acute GVHD and isolated from patients with acute GVHD. Con-
trary to our expectation that PD-L1 would act to suppress the in vivo 
T cell response, we observed a novel T cell–intrinsic function for 
PD-L1 in promoting murine GVHD via optimizing the metabolic 
activity and survival of alloreactive T cells. These findings suggest 
that selective PD-L1 reduction in donor T cells may provide a new 
therapeutic strategy for inhibiting GVHD lethality, an approach 
that may be applicable to other diseases as well.
Results
Decreased GVHD mortality caused by PD-L1–deficient donor T cells. 
PD-1 and PD-L1 are known T cell activation antigens, but their 
expression had not been analyzed in the context of GVHD. To do 
so, lethally irradiated C57BL/6 (B6) or BALB/c recipients were 
infused with WT B6 bone marrow (BM) and B6 Ly5.2 spleen cells 
to induce GVHD. On day 5 after BMT, PD-1 and PD-L1 expression 
on allogenic donor T cells was significantly increased compared 
with that on syngeneic donor T cells and T cells from naive con-
trols (Figure 1, A and B). PD-1 and PD-L1 induction was severely 
impaired in Ifngr1–/– donor T cells, indicating that elevated IFN-γ 
during GVHD contributes to their upregulation (Supplemental 
Figure 1, A and B; supplemental material available online with this 
article; doi:10.1172/JCI85796DS1). In contrast to these observa-
tions with PD-1 and PD-L1, less than 4% of donor T cells expressed 
PD-L2 during the GVHD response (Supplemental Figure 1C).
While PD-L1 is constitutively expressed at low levels on mouse 
T cells, its expression is inducible on human T cells. To investi-
gate PD-L1 expression on human T cells, T cells isolated from 
PBMCs of normal healthy donors were stimulated with Human 
T-Expander anti–CD3/CD28 beads for 3 days, and T cells then 
were analyzed daily for PD-L1 expression. Following stimulation, 
there was a marked increase in PD-L1 expression on both CD4 
Figure 2. Pdl1–/– versus WT donor T cells have reduced expression of gut 
homing and chemokine receptors, and inflammatory cytokines in spleen. 
Lethally irradiated BALB/c recipients were infused with 107 WT B6 BM cells 
plus 2 × 106 WT B6 or Pdl1–/– purified T cells. Mice were sacrificed (n = 5 per 
group) on day 7 after BMT, and donor CD4 and CD8 T cells in spleen were 
analyzed by flow cytometry for the expression of CD25, CD62L, and CD44 
(A), LPAM-1 (B and C), CCR9 (D), and CXCR3 (E). MFI, mean fluorescence 
intensity. (F–I) Intracellular cytokine staining was performed on day 7 after 
BMT to detect the number of donor T cells producing IFN-γ, TNF-α, IFN-γ/
TNF-α, IL-6, or IL-17. (A–I) Data are representative of 2–3 independent 
experiments. Data represent mean ± SEM, and P values were calculated by 
2-tailed t test (A and C–I). *P < 0.05, **P < 0.01, ***P < 0.001.
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B6 CD45.1+ BM cells plus CD25-depleted CD45.2+ WT B6 or 
Pdl1–/– purified T cells. Donor T cell–derived CD4+Foxp3+ Tregs 
in spleen showed a very modest increase in frequency and inten-
sity in recipients of Pdl1–/– versus WT T cells with mean frequency 
less than 2.5% on day 7 after BMT in both groups (Supplemen-
tal Figure 4A). The mean frequencies of donor T cell–derived 
CD4+Foxp3+Helios+, CD4+Foxp3+CD304+, and CD4+Foxp3+ 
PD-1+ Tregs were <1.2%, 1.4%, and 1.7%, respectively, with no 
differences in recipients of WT versus Pdl1–/– donor T cells (data 
not shown), whereas mean frequencies of WT donor BM-derived 
CD4+Foxp3+ and CD4+Foxp3+Helios+ Tregs were increased up to 
9.0% on day 14 after BMT with no differences in recipients of 
WT versus Pdl1–/– donor T cells (Supplemental Figure 4B and data 
(Figure 4A and data not shown). However, despite the ability of 
activation to induce both PD-1 and PD-L1 on Tregs, we found no 
functional defect in Pdl1–/– Tregs. In vitro, Pdl1–/– Tregs suppressed 
effector T cell (Teff) proliferation more effectively than WT Tregs 
(Figure 4B). Moreover, in vivo, in a system where supplementary 
Tregs are used to mitigate GVHD, Pdl1–/– Tregs were as effective 
as WT Tregs in improving survival of the animals (Figure 4C), 
whereas Pdl1–/– Teffs in the absence of Tregs were unable to cause 
the same severity of GVHD lethality as WT Teffs in the absence 
of Tregs (Figure 4D).
We next investigated whether Pdl1–/– donor T cells would 
influence the expansion of induced Tregs (iTregs) following allo-
BMT. Lethally irradiated BALB/c recipients were infused with 
Figure 3. Pdl1–/– versus WT donor T cells promote less gut injury in recipients. Lethally irradiated BALB/c recipients were infused with 107 WT B6 BM cells 
alone or with 2 × 106 WT B6 or Pdl1–/– purified T cells. (A) Mice were sacrificed on day 24 after BMT (n = 5–7 per group), and H&E-stained tissue sections 
were scored for GVHD. (B–F) Lethally irradiated BALB/c mice were infused with 107 WT B6 BM cells plus 2 × 106 WT B6 or Pdl1–/– purified T cells. Mice were 
sacrificed on day 24 after BMT (n = 10 per group), and lymphocytes isolated from colon (2 colons were pooled to make 1 pooled sample and 5 pooled sam-
ples per group) were analyzed by flow cytometry. (B) Donor T cells were analyzed for total cell numbers or intracellular expression of Ki-67. (C–F) Intracellu-
lar cytokine staining was performed to detect the number of donor T cells producing IFN-γ, TNF-α, IL-6, or IFN-γ/TNF-α. (G) FITC-dextran was administered 
orally on day 24 after BMT (n = 5–7 per group), and plasma levels were measured after 4 hours. (A–G) Data are representative of 2 independent experi-
ments. Data represent mean ± SEM, and P values were calculated by 2-tailed t test (A–G). *P < 0.05, **P < 0.01, ***P < 0.001.
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not shown). These data are consistent with our previous findings 
that iTregs fail to be generated in high number in vivo because of 
IL-21 production during acute GVHD (30).
Together these data argue that despite expression of PD-L1 on 
activated T cells, it was cell-intrinsic differences in Teffs that were 
responsible for reduced lethality in recipients of Pdl1–/– donor T cells.
Higher expression of inhibitory receptors by Pdl1–/– donor T cells leads 
to reduced Teff function. Given the data above suggesting that reduced 
Teff function is responsible for the reduction in GVHD caused by 
Pdl1–/– donor T cells, we next investigated inhibitory receptor expres-
sion early after BMT. A cotransfer strategy was used in which equal 
numbers of congenically marked WT and Pdl1–/– T cells were infused 
along with BM into lethally irradiated BALB/c recipients to directly 
compare donor T cell responses in same recipient mice. We observed 
that Pdl1–/– donor T cells had increased expression of CTLA-4 and 
Lag-3 on both CD4 and CD8 T cells, and increased expression of 
Tim-3 on CD8 T cells (Figure 5, A–C). Higher expression of multi-
ple inhibitory receptors by Pdl1–/– donor T cells was associated with 
reduced IFN-γ and granzyme B production (Figure 5, D–F). Com-
parable results were also obtained in recipient mice coinfused with 
Figure 4. Reduced GVHD lethality in recipients of Pdl1–/– versus WT donor T cells is independent of donor Treg function. (A) Tregs were isolated from 
naive WT BALB/c mice and were cultured with recombinant human IL-2 and CD3/CD28 beads. CD4+CD25+Foxp3+ cells were analyzed by flow cytometry for 
PD-1, PD-L1, and PD-L2 expression on day 4, day 7, and day 11. Shaded histogram: isotype-matched control Ab. (B) Tregs were isolated from naive WT B6 
or Pdl1–/– mice. Naive B6 Ly5.2 mouse splenocytes were labeled with CFSE and used as responder cells. Responder cells were stimulated with anti-mCD3 
Ab and were cultured with or without freshly isolated Tregs. T cell proliferation was determined by CFSE dilution on day 4 using flow cytometry. (A and B) 
Data are representative of 2 independent experiments. (C) Lethally irradiated BALB/c recipients were infused with 107 WT B6 BM cells alone, or with 1 × 106  
WT B6 purified T cells, or with 1 × 106 WT B6 purified T cells plus 1 × 106 WT B6 purified Tregs or 1 × 106 Pdl1–/– purified Tregs. Kaplan-Meier survival plot 
represents pooled data from 2 independent experiments (n = 16–22 per group; WT T cells vs. WT T cells + WT Tregs, P = 0.0014; WT T cells vs. WT T cells + 
Pdl1–/– Tregs, P = 0.0004). (D) Lethally irradiated BALB/c recipients were infused with 107 WT B6 BM cells alone, or with 2 × 106 WT B6 or Pdl1–/– purified T 
cells, or with 2 × 106 WT B6 or Pdl1–/– CD25-depleted purified T cells. Kaplan-Meier survival plot represents pooled data from 2 independent experiments  
(n = 16–18 per group; WT T cells vs. WT CD25-depleted T cells, P = 0.0003; Pdl1–/– T cells vs. Pdl1–/– CD25-depleted T cells, P = 0.2306; WT vs. Pdl1–/– T cells,  
P < 0.0001). (B) Data represent mean ± SEM. P values were calculated by 2-tailed t test (B) or log-rank test (C and D). **P < 0.01, ***P < 0.001.
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Figure 5. Higher expression of multiple inhibitory receptors by Pdl1–/– donor T cells leads to reduced Teff function. (A–F) Lethally irradiated BALB/c 
recipients were coinfused with 7.5 × 106 B6 Ly5.2+ purified T cells plus 7.5 × 106 Pdl1–/– purified T cells along with 107 WT B6 BM cells. Mice were sacrificed on 
day 3 after BMT (n = 5–10 per group), and donor T cells in spleen were analyzed by flow cytometry for the expression of Lag-3 (B) or Tim-3 (C) or intracel-
lular expression of CTLA-4 (A), IFN-γ (D and E), or granzyme B (F). (G and H) Purified T cells from B6 Ly5.2 mice and Pdl1–/– mice were cocultured in the 
presence of suboptimal concentration of plate-bound anti-mCD3 (coating density 5 μg/ml) and soluble anti-mCD28 (1 μg/ml). Cells were harvested on 
day 4 and analyzed by flow cytometry for the expression of Lag-3, TIGIT, or intracellular expression of CTLA-4 or IFN-γ. (A–H) Data are representative of 2 
independent experiments. Data represent mean ± SEM, and P values were calculated by 2-tailed t test (A–C and E–H). *P < 0.05, **P < 0.01, ***P < 0.001.
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
2 6 4 9jci.org   Volume 126   Number 7   July 2016
tion using WT B6 or Pdl1–/– purified T cells as responders and BALB/c 
BM-derived DC stimulators, we observed significantly decreased 
responder frequency of Pdl1–/– T cells (Supplemental Figure 5). Sim-
ilar findings of decreased proliferation were observed in vivo in a 
model where lethally irradiated BALB/c mice were infused with WT 
B6 BM cells plus CFSE-labeled WT B6 or Pdl1–/– splenocytes. Here, 
we observed a reduction in donor T cells in the spleens of animals 
that received Pdl1–/– cells (Figure 6A), coupled with a lower responder 
frequency and proliferation capacity (Figure 6B).
equal numbers of WT and Pdl1–/– spleen cells (data not shown). Con-
sistent with these in vivo studies, we found that following in vitro 
stimulation with suboptimal anti-CD3 plus anti-CD28, Pdl1–/– T 
cells had increased expression of multiple inhibitory receptors and 
reduced IFN-γ production (Figure 5, G and H).
PD-L1 expression on donor T cells is important for their expansion 
and survival. We next undertook studies to investigate potential 
mechanisms for diminished GVHD induced by Pdl1–/– donor T cells; 
first, T cell proliferation was evaluated. In a mixed lymphocyte reac-
Figure 6. PD-L1 expression on donor T cells is important for their 
expansion and survival. (A–E) Lethally irradiated BALB/c recipients 
were infused with 107 WT B6 BM cells plus 20 × 106 CFSE-labeled WT B6 
or Pdl1–/– splenocytes. Mice were sacrificed on day 4 after BMT, and sple-
nocytes were analyzed by flow cytometry. Donor T cells were analyzed 
for total cell numbers (A), CFSE dilution (B), annexin V (C), FasL (D), or 
TMRM expression (E). (F and G) Lethally irradiated BALB/c recipients 
were infused with 107 WT B6 BM cells plus 2 × 106 WT B6 or Pdl1–/– 
purified T cells. (F) Intracellular staining was performed on day 5 and 
analyzed by flow cytometry to detect the percentage of splenic donor T 
cells expressing Bcl-xL and Ki-67. (G) Splenocytes were also analyzed on 
day 5 to detect the percentage of donor T cells expressing CD127. (A–G) 
Data are representative of at least 5 mice per group from 2–3 inde-
pendent experiments. Data represent mean ± SEM, and P values were 
calculated by 2-tailed t test (A–G). *P < 0.05, **P < 0.01, ***P < 0.001.
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Bcl-xL and of expression of CD127 (the 
IL-7Rα chain that transduces cell survival 
signals) in Pdl1–/– donor T cells, without dif-
ferences in Bim and Bcl-2 expression (Fig-
ure 6, F and G, and data not shown). Taken 
together, these data suggest that PD-L1 
expression on donor T cells is required for 
both optimal cell expansion and cell survival.
WT and Pdl1–/– donor T cells have identi-
cal signaling pattern. The findings above of 
decreased proliferation and survival sug-
gested that loss of PD-L1 expression on donor 
T cells might result in altered T cell signal-
ing. Since little is known about PD-L1 as a T 
cell signaling molecule, we used an unbiased 
approach to examine total signaling by phos-
photyrosine (Figure 7A) and also interrogated 
a selected number of molecules (Akt, ZAP70, 
and PKC-θ; Figure 7B) known to be important 
for T cell signaling (32, 33). We observed no 
differences between WT and Pdl1–/– donor T 
cells on day 5 or day 7 after BMT, suggesting 
that loss of PD-L1 expression does not intrin-
sically change several known key T cell sig-
naling pathways.
Metabolic alterations in Pdl1–/– donor T cells 
during GVHD. To gain further insight into 
PD-L1 function on T cells, transcriptional pro-
filing of donor T cells was performed on day 
5 after BMT from GVHD recipients of WT or 
Pdl1–/– donor T cells. Individual genes were ana-
lyzed for differential expression using the sig-
nificance analysis of microarrays method (34), 
with the FDR threshold set at 0.20 for a highly 
sensitive analysis. A heat map of relative gene 
expression values for CD4 and CD8 T cells is 
shown (Figure 8, A and B). Somewhat unex-
pectedly, we did not find significant differences 
in individual genes associated with apoptosis. 
The majority of genes that were differentially 
expressed were increased in WT T cells. A small 
group of genes included in Kyoto Encyclope-
dia of Genes and Genomes (KEGG) metab-
olism gene sets had increased expression in 
Pdl1–/– CD8 T cells. Using the QuSAGE method 
(35) applied to pathways from KEGG (36), we performed pathway 
analysis to evaluate whether nonsignificant expression differences 
in multiple genes comprising 1 or more pathways can provide evi-
dence of significant differences in overall pathway expression. The 
apoptosis pathway along with a number of metabolism pathways 
had increased expression, whereas 4 pathways (pyrimidine metabo-
lism, protein export, proteasome, and ribosome) showed decreased 
expression in Pdl1–/– donor T cells (Figure 8C).
The finding of alterations in metabolic pathways prompted a 
more detailed functional metabolic analysis. In GVHD, donor T 
cells proliferate rapidly in response to host alloantigenic dispar-
ities before migration to specific target organs where they exert 
Total cell recovery is a function of both proliferation and 
survival. In addition to diminished proliferation of Pdl1–/– donor 
T cells, we also noted increased cell death, as assessed by stain-
ing with annexin V and FasL (Figure 6, C and D). To determine 
whether mitochondrial apoptosis contributed to the increased 
cell death rate in Pdl1–/– donor T cells, we measured tetramethyl-
rhodamine (TMRM), which does not accumulate in depolarized 
mitochondria and decreases during apoptosis (31). Pdl1–/– donor 
T cells underwent more apoptosis as demonstrated by dimin-
ished intensity of TMRM staining (Figure 6E). Analysis of Bcl-xL, 
Bim, and Bcl-2, key mediators of the mitochondrial apoptotic 
pathway, revealed decreased levels of the antiapoptotic protein 
Figure 7. WT and Pdl1–/– donor T cells have identical signaling patterns. Lethally irradiated 
BALB/c recipients were infused with 107 WT B6 BM cells plus 2 × 106 WT B6 or Pdl1–/– purified T 
cells. Mice were sacrificed (n = 10 per group) on day 5 or day 7 after BMT, and donor T cells were 
purified from spleen (3–4 spleens were pooled to make 1 pooled sample and 3 pooled samples 
per group). (A) Cell lysates were prepared from unstimulated or pervanadate-stimulated donor T 
cells, and phosphotyrosine Western blot analysis was performed. (B) Cell lysates were prepared 
from unstimulated T cells and probed for phospho-Akt, ZAP70, β-actin, and phospho–PKC-θ for 
Western blot analysis. Data are representative of 2–3 independent experiments.
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
2 6 5 1jci.org   Volume 126   Number 7   July 2016
lism, we found that the expression of GLUT1 (the major glucose 
transporter on hematopoietic cells) (44) was significantly lower 
in proliferating Pdl1–/– donor T cells from BMT recipients (Fig-
ure 9A), suggesting decreased glucose uptake and metabolism. 
Consistent with this, measurements of the extracellular acidifi-
cation rate (ECAR) in donor T cells isolated from BMT recipients 
showed a reduced ECAR in Pdl1–/– donor T cells following expo-
sure to glucose, as well as a reduction in their maximal glycolytic 
effector function. To fulfill the bioenergetic and biosynthetic 
demands of proliferation, migration, and cytolysis, T cells repro-
gram their metabolic pathways for a number of substrates, includ-
ing glucose (37, 38), glutamine (39, 40), and fatty acids (FAs) (41, 
42). Therefore, we compared each of these metabolic pathways in 
WT and Pdl1–/– donor T cells after allogeneic BMT.
Activated T cells preferentially generate ATP through aero-
bic glycolysis (43). Focusing first therefore on glucose metabo-
Figure 8. Unsupervised clustering of differentially expressed genes in WT versus Pdl1–/– donor T cells during GVHD. Lethally irradiated BALB/c recipients 
were infused with 107 WT B6 BM cells plus 2 × 106 WT B6 or Pdl1–/– purified T cells. Mice were sacrificed (n = 15 per group) on day 5 after BMT, and donor 
CD4 and CD8 T cells were purified separately from spleen (5 spleens were pooled to make 1 pooled sample and 3 pooled samples per group). Differential 
expression between WT versus Pdl1–/– donor CD4 (A) and CD8 (B) T cells was analyzed using SAM. Unsupervised hierarchical clustering on genes that 
were differentially expressed at an FDR of 0.20 was done and a heat map generated to describe the results. Each column represents an individual pooled 
sample, and each row represents a single gene. Expression values are scaled by rows with values greater than mean shown in red and values less than 
mean shown in green, with intensity of color corresponding to relative level of expression. Genes with membership in a KEGG metabolism gene set are 
highlighted with text labels. (C) Pathway analysis of WT versus Pdl1–/– donor T cells during GVHD. Differential expression of genes comprising various KEGG 
pathways was tested using QuSAGE, with CD4 and CD8 T cell samples pooled into WT and Pdl1–/– groups (n = 6 pooled samples per group). A list of gene 
sets included in the analysis is shown in Supplemental Table 2. Gene sets with relative expression differences found at an FDR of 0.20 are shown, along 
with 95% confidence intervals for the expression difference. P values for C were calculated using the QuSAGE method (35).
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Figure 9. Glucose and glutamine metabolism alterations in Pdl1–/– donor T cells during GVHD. Lethally irradiated Thy1.1+ BALB/c recipients were infused 
with 107 WT B6 BM cells plus 20 × 106 CellTrace Violet–labeled (CTV-labeled) or unlabeled WT B6 or Pdl1–/– splenocytes. Lethally irradiated Thy1.1+ B6 recip-
ients were infused with 107 WT B6 BM cells plus 20 × 106 CTV-labeled or unlabeled WT B6 splenocytes and used as syngeneic control. Mice were sacrificed 
on day 4 after BMT, and experiments were performed as described. (A) Splenocytes were analyzed by flow cytometry for intracellular expression of GLUT1 
in undivided (CTVhi) and divided (CTVlo) donor T cells. (B) ECAR of purified donor T cells was measured after addition of glucose, oligomycin, and 2-deoxy-
glucose (2-DG). (C) Basal glycolysis was measured after addition of glucose, and glycolytic capacity was measured after addition of oligomycin. (D) OCR of 
purified donor T cells was measured after addition of oligomycin, fluorocarbonyl cyanide phenylhydrazone (FCCP), and antimycin A. (E) Basal OCR (resting 
OCR – antimycin A OCR) was measured before addition of oligomycin, and maximal OCR was measured after addition of FCCP subtracting nonmitochon-
drial OCR (antimycin A OCR). (F) Splenic donor T cells were analyzed by flow cytometry for CD98 expression. (G and H) Purified donor T cells were cultured 
at 37°C for 4 hours. Culture supernatants were collected, and glutamine consumption and glutamate production were measured using a NovaFlex analyzer. 
ND, not detected. (B, D, and F–H) T cells purified from naive WT B6 mice (n = 4) were included as control. (A and F) Data are representative of 5 mice per 
group from 2–3 independent experiments. (B–E, G, and H) Data are representative of 12 mice per group from 2–3 independent experiments. Data represent 
mean ± SEM. P values were calculated by 2-tailed t test (A, C, and E–H). *P < 0.05, **P < 0.01, ***P < 0.001.
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Figure 10. FA metabolism alterations in Pdl1–/– donor T cells during GVHD. (A–E) Lethally irradiated Thy1.1+ BALB/c mouse recipients infused with 107 WT 
B6 BM cells plus 20 × 106 CTV-labeled or unlabeled WT B6 or Pdl1–/– splenocytes. Lethally irradiated Thy1.1+ B6 recipients were infused with 107 WT B6 BM 
cells plus 20 × 106 CTV-labeled or unlabeled WT B6 splenocytes and used as syngeneic control. Mice were sacrificed on day 4 after BMT, and experiments 
were performed as described. Splenic donor T cells were analyzed by flow cytometry for BoDipy (A) and CD36 (B) expression. (C) Splenocytes were also 
analyzed by flow cytometry for intracellular expression of CPT1a in undivided and divided donor T cells. (A–C) Data are representative of 5 mice per group 
from 2–3 independent experiments. (D and E) OCR of purified donor T cells was measured after addition of oligomycin, FCCP, etomoxir (Eto), and antimycin 
A. Data are representative of 12 mice per group. (A and D) T cells from naive WT B6 mice (n = 4) were included as control. (F–H) Reduced apoptosis and 
enhanced metabolic activities in WT versus Pdl1–/– donor T cells are intrinsic properties of donor T cells. Lethally irradiated BALB/c recipients were coin-
fused with 15 × 106 B6 Ly5.2+ splenocytes plus 15 × 106 Pdl1–/– splenocytes along with 107 WT B6 BM cells. Recipient mice were treated with isotype-matched 
control Ab or anti–PD-L1 blocking mAb. Donor T cells in spleen were analyzed on day 4 after BMT (n = 5 mice per group) for DHE (F), or intracellular 
expression of GLUT1 (G) or CPT1a (H) by flow cytometry. Data are representative of 2 independent experiments. Data represent mean ± SEM. P values were 
calculated by 2-tailed t test (A–C and E–H). *P < 0.05, **P < 0.01, ***P < 0.001.
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Figure 11. Pdl1–/– donor T cells retain GVL 
effects. (A, B, and E) Lethally irradiated 
BALB/c recipients were infused with 107 T 
cell–depleted WT B6 BM cells plus 3 × 105 
A20luc-lymphoma cells or with 1 × 106 WT 
B6 or Pdl1–/– purified T cells (n = 8 mice 
per group) on day 0. (C, D, and F) Lethally 
irradiated BALB/c recipients were infused 
with 107 T cell–depleted WT B6 BM cells 
plus 1 × 106 A20luc-lymphoma cells or 
with 1 × 106 WT B6 or Pdl1–/– purified T 
cells (n = 8 mice per group) on day 0. (A 
and C) Tumor growth was monitored by 
luciferase imaging on day 7, day 14, day 21, 
day 27, day 35, day 41, day 48, day 55, and 
day 62 after BMT. BLI, bioluminescence 
imaging. (B) Kaplan-Meier survival plot 
of transplanted mice is shown (recipi-
ents of WT vs. Pdl1–/– donor T cells, P = 
0.0092). (D) Kaplan-Meier survival plot of 
transplanted mice is shown (recipients of 
WT vs. Pdl1–/– donor T cells, P = 0.046). (E 
and F) In vivo bioluminescence imaging of 
A20luc-lymphoma cells on day 14 and day 
27 after BMT. The scale to the right of the 
images describes the color map for the 
photon count. P values were calculated by 
log-rank test (B and D). (A–F) Data were 
obtained from 1 experiment.
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PD-L1 versus rat IgG (Figure 10G). CPT1a expression was also 
significantly higher in WT versus Pdl1–/– donor T cells in recipients 
treated with rat IgG or anti–PD-L1 (Figure 10H). These data sug-
gest that reduced apoptosis and increased metabolic activities of 
WT versus Pdl1–/– donor T cells may be due to intrinsic differences 
in these donor T cells.
Pdl1–/– donor T cells retain graft-versus-leukemia effects. Because 
Pdl1–/– donor T cells could ameliorate acute GVHD, we sought to 
determine whether they could retain graft-versus-leukemia (GVL) 
without inducing lethal GVHD.
Lethally irradiated BALB/c recipients were infused with WT B6 
T cell–depleted BM plus A20luc-lymphoma cells (3 × 105 or 1 × 106) 
on day 0. WT B6 or Pdl1–/– T cells also were administered to groups 
of mice on day 0. Mice that received T cell–depleted BM and A20luc 
(3 × 105) alone died by day 48 after BMT because of tumor burden 
(Figure 11, A and B). Mice that received A20luc (3 × 105) along with 
WT or Pdl1–/– donor T cells had no tumor growth (Figure 11, A and 
E) and died because of GVHD (Figure 11B). GVHD was amelio-
rated in recipients of Pdl1–/– versus WT donor T cells (Figure 11B), 
resulting in a significant increase in overall survival rates.
To address whether increased tumor burden would alter GVL 
effects, cohorts of recipients were infused with 3 times the lethal 
dose of A20luc-lymphoma cells. Mice that received A20luc (1 × 106) 
along with WT or Pdl1–/– donor T cells had no tumor growth (Fig-
ure 11, C and F) and died because of GVHD (Figure 11D), again 
resulting in a significant increase in survival rates in recipients of 
Pdl1–/– donor T cells, whereas mice that received T cell–depleted 
BM and A20luc (1 × 106) alone died by day 28 after BMT because of 
higher tumor burden (Figure 11, C and D). These data suggest that 
Pdl1–/– donor T cells can mediate GVL effects in a similar manner 
to that of WT donor T cells without increasing GVHD.
Discussion
The PD-1/PD-L1 pathway is a key immune checkpoint that helps 
regulate normal self-tolerance, but is now known to play a key 
role in damping immune responses to persistent antigenic stimuli 
such as chronic viral infections and many malignancies (47, 48). 
As such, mAbs that block PD-1 or PD-L1 enable “exhausted” T 
cells to regain normal functional capacities, secrete proinflam-
matory cytokines, and support productive immune responses 
(49–51). Consistent with the role in immune augmentation, stud-
ies using genetic models in which PD-1 is absent on T cells and 
experiments using blocking Abs or fusion proteins demonstrate 
that blocking PD-1 expression or engagement on donor T cells 
markedly enhances GVHD lethality (52). In striking contrast, 
we report here that the in vivo upregulation of PD-L1 on GVHD-
causing CD4 and CD8 T cells is necessary for their survival, pro-
liferation, and optimal Teff function.
Expression of PD-L1 on activated WT donor T cells was 
associated with decreased apoptosis, and increased expres-
sion of antiapoptotic molecules including Bcl-xL, which itself 
is induced by TCR stimulation and upregulated by CD28 sig-
nals (53). Elevated expression of Bcl-xL prevents T cell death 
in response to cytokine withdrawal and Fas/FasL signaling 
(53–55). Our finding of lower Bcl-xL and higher FasL expression 
on Pdl1–/– donor T cells during GVHD provides a downstream 
mechanism to explain the higher apoptosis and lower absolute 
capacity (after the subsequent addition of oligomycin to suppress 
mitochondrial ATP production) (Figure 9, B and C).
An alternative mechanism of energy generation is oxidative 
metabolism, which can use glucose, glutamine, or FAs as sub-
strates. As expected, the O2 consumption rate (OCR), an indica-
tor of oxidative phosphorylation (OXPHOS), was significantly 
elevated in allogeneic versus syngeneic donor T cells (Figure 9D). 
Similar to the findings seen with glycolysis, both basal OCR and 
maximal respiratory capacity (after fluorocarbonyl cyanide phe-
nylhydrazone treatment) were significantly reduced in Pdl1–/– ver-
sus WT donor T cells (Figure 9E).
Glutamine, a key amino acid for T cell activation, serves as an 
amine group donor for nucleotide synthesis. Glutamate (the first 
product of glutamine metabolism) can be converted into α-keto-
glutarate, which can be metabolized through the TCA cycle to 
generate citrate, providing a 2-step pathway for glutamine to enter 
energy metabolism. Consistent with lessened GVHD, we found 
that cell surface expression of CD98 (glutamine transporter; Fig-
ure 9F) and glutamine consumption (Figure 9G) and glutamate 
production (Figure 9H) were significantly reduced in Pdl1–/– versus 
WT donor T cells.
We also examined FA oxidation (FAO) as an additional means 
of energy utilization. We hypothesized that FAO would be lower in 
Pdl1–/– donor T cells because PD-1 ligation of activated T cells can 
limit glycolysis and amino acid metabolism while increasing FAO 
(45), and GVHD Teffs are under high metabolic stress and known 
to utilize FAO to provide energy for their survival and/or function. 
We first measured FA uptake using BoDipyC1–C12, a fluorescent FA 
analog, and found that it was significantly reduced in Pdl1–/– donor 
T cells (Figure 10A). Consistent with reduced FA uptake, surface 
expression of CD36, a receptor that binds long-chain FA (46), was 
significantly reduced in Pdl1–/– donor T cells (Figure 10B). We next 
analyzed FAO by donor T cells. CPT1a, a metabolic enzyme that 
controls the rate-limiting step in mitochondrial FAO, was also sig-
nificantly reduced in proliferating Pdl1–/– versus WT donor T cells 
(Figure 10C). The use of etomoxir, a specific inhibitor of CPT1a, 
significantly inhibited maximal respiratory capacity of WT versus 
Pdl1–/– donor T cells (Figure 10, D and E), confirming that mito-
chondrial FAO was higher in WT than in Pdl1–/– donor T cells.
To address whether increased metabolic activity of WT com-
pared with Pdl1–/– donor T cells was due to increased GVHD or 
intrinsic features of donor T cells, we performed experiments to 
directly compare the metabolic activity of WT versus Pdl1–/– donor T 
cells within an individual recipient that has or does not have active 
GVHD. Lethally irradiated BALB/c recipients were coinfused 
with B6 Ly5.2+ splenocytes plus Pdl1–/– splenocytes along with WT 
B6 BM to induce GVHD. To determine whether the absence of 
PD-L1 engagement with its receptors contributed to any observed 
metabolic changes, cohorts of recipients were treated with iso-
type-matched control Ab or anti–PD-L1 mAb (10F.9G2) that blocks 
all known PD-L1 interactions. Splenocytes were analyzed on day 4 
after BMT. WT versus Pdl1–/– donor T cells contained significantly 
less superoxide (measured by dihydroethidium expression) in 
recipients treated with rat IgG or anti–PD-L1 (Figure 10F). GLUT1 
expression was increased in WT donor T cells in recipients treated 
with rat IgG, and GLUT1 expression was significantly upregulated 
on both WT and Pdl1–/– donor T cells in recipients treated with anti–
The Journal of Clinical Investigation R e s e a R c h  a R t i c l e
2 6 5 6 jci.org   Volume 126   Number 7   July 2016
highly inflammatory environment. These speculations, as well as 
differences in time points examined, may be responsible for the 
observed utilization of FAO by T cells in our and a prior study (45), 
in contrast to the recent publication (71).
Collectively, we postulate that relative deficiencies in glycol-
ysis, OXPHOS, and FAO create a metabolic crisis in Pdl1–/– Teffs 
during GVHD. The high proliferative rate and metabolic needs of 
GVHD Teffs is outstripped in Pdl1–/– Teffs, leading to a heightened 
stress response as measured by higher superoxide production 
and reduced TMRM accumulation in depolarized mitochondria. 
It is particularly intriguing to note that these resultant metabolic 
consequences drive Teffs toward an exhausted T cell profile, 
characterized by lower proliferation, proinflammatory cytokine 
production, cytolytic granule expression, and higher expression 
of coinhibitory molecules including CTLA-4, Lag-3, TIM-3, and 
TIGIT, while maintaining PD-1 expression (72, 73).
Nonetheless, because PD-L1 is involved in normal thymic 
selection (74), it is possible that the properties of Pdl1–/– T cells 
observed here may relate to developmental issues (e.g., those that 
impair function or alter TCR repertoire) or to PD-L1 expression on 
non-T cells. Future studies using models where Pdl1 is knocked out 
selectively in T cells at later stages of development or in peripheral 
T cells would be needed to precisely address this alternative expla-
nation. Lastly, the reasons for the observed biologic and metabolic 
effects remain unknown. Possibilities include the lack of PD-L1 
signaling in trans to PD-1+ cells (both donor and residual T cells), 
potential effects of PD-L1 on T cell adhesogenic properties, and 
colocalization of membrane signaling domains such as would 
occur in lipid rafts or intracellular adapter proteins to bolster sig-
naling via other pathways.
Whereas PD-L1 signaling of Teffs can regulate the develop-
ment, maintenance, and function of induced Tregs (75), the func-
tion of PD-L1 expressed on thymic-derived Tregs has not been 
reported to our knowledge. Given the low survival and metabo-
lism of Pdl1–/– Teffs during GVHD, we would have expected func-
tional defects in Pdl1–/– Tregs, particularly taking into account the 
defect in FAO used as a major cellular energy source of Tregs. 
Instead, we found that Pdl1–/– Tregs transferred in vivo had com-
parable GVHD suppressor cell potency. Furthermore, using 
Treg-depleted donor grafts, we demonstrate that Pdl1–/– Teffs, in 
the absence of donor thymic-derived Tregs, are unable to cause 
the same severity of GVHD lethality as WT Teffs. Finally, amelio-
rated GVHD by Pdl1–/– donor T cells would favor iTreg generation 
based on lower inflammatory response such as IL-21; however, 
the findings were very modest, transient, and much lower than 
iTregs derived from WT donor BM, suggesting that a fundamen-
tal difference is occurring in the absence of T cell PD-L1 as the 
dominant reason for lower GVHD severity. Importantly, GVL 
effects against A20 lymphoma were largely maintained, despite 
markedly decreased GVHD lethality in recipients of Pdl1–/– donor 
T cells. As a therapeutic strategy, directed PD-L1 targeting of 
donor T cells by genome engineering or RNA inhibition may be 
highly advantageous, as Treg suppressor cell potency would be 
intact while Teffs would be impaired.
Taken together, our results demonstrate the functional sig-
nificance of PD-L1 expressed by donor T cells in regulating acute 
GVHD. Greater understanding of the function of PD-L1 expres-
numbers of Pdl1–/– T cells in the spleen and intestine of GVHD 
mice. One feature that likely contributes to reduced levels of 
Bcl-xL is lower CD127 expression in Pdl1–/– T cells. IL-7 signaling 
via CD127 promotes the upregulation of Bcl-xL along with Bcl-2 
in CD4 effector/memory T cells (56). Also, CD127 signaling 
is necessary but not sufficient for formation of memory CD8 
T cells during viral infection (57, 58) and for the transition of 
CD4 Teffs into memory cells (59). Together, these findings of 
reduced CD127 expression and enhanced apoptosis in both CD4 
and CD8 Pdl1–/– GVHD Teffs provide a mechanistic explanation 
for how loss of the PD-L1 on T cells may compromise the gener-
ation of protective antitumor immunity (60).
The intense metabolic demand of T cells in response to 
activation leads to a series of metabolic adaptations to facilitate 
expansion and differentiation. These include induction of aero-
bic glycolysis (61), OXPHOS (62), glutaminolysis, and increase in 
synthesis of biomolecules (63). T cell metabolism has also been 
shown to require lipid synthesis (64) or oxidation (65) and amino 
acid uptake (66). We (22) and others (67) have shown that GVHD 
results in high metabolic demands for Teffs, increasing their 
dependency on aerobic glycolysis. Glucose uptake provides a key 
metabolic control point through the GLUT family of glucose trans-
porters. GLUT1 can promote Teff, as transgenic GLUT1 overex-
pression selectively increases Teff frequency and leads to inflam-
matory disease (38, 42), whereas GLUT1 deficiency decreases 
Teff expansion and the ability to induce inflammation (68). We 
found a significant increase in GLUT1 expression in proliferating 
WT donor T cells along with increased glycolysis and OXPHOS. 
Decreased glucose uptake by proliferating Pdl1–/– donor T cells 
may result in reduced contribution of glucose as a biosynthetic 
precursor and compromise proliferation. These data are consis-
tent with a recent report showing that tumor cell expression of 
PD-L1 serves to facilitate glucose uptake and glycolysis, and that 
checkpoint inhibition acts to restore glucose availability to T cells 
in the tumor microenvironment, enabling proliferation and cytok-
ine production (69).
Although memory T cells preferentially utilize FA metabolism 
(41, 70), Teffs can also rely on FAO during GVHD (65). Increased 
FA uptake and FAO, and enhanced susceptibility to pharmaco-
logic inhibition of FAO by etomoxir in WT donor T cells, sug-
gest that PD-L1 provides a cell-intrinsic positive stimulus for FA 
metabolism in alloreactive T cells undergoing clonal expansion, 
which may further support T cell survival, extending in vitro stud-
ies by others using human T cells (45). Additionally, the reduced 
capacity of Pdl1–/– Teffs to optimally create energy from glycolysis 
and FAO is not compensated by increasing OXPHOS, as evident 
by lower OCR rates or increasing mitochondrial mass (data not 
shown). Here we show that donor T cells expressing PD-L1 drive 
concurrent increase in glucose and FA metabolism in the con-
text of alloantigenic stimuli. In contrast, a recent study showed a 
decreased reliance on FA metabolism in alloreactive T cells (71). 
It is likely that differences in the nature and strength of alloan-
tigenic stimuli along with the BMT conditions and other factors 
(e.g., microbiome) that differ between laboratories may lead to 
models with varying degrees of severity (and hence rapidity of 
lethality), which may alter the metabolic requirements and path-
ways engaged to meet the needs of highly proliferative T cells in a 
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was measured using an annexin V staining kit. Superoxide produc-
tion by donor T cells was measured by flow cytometry using DHE (a 
redox-sensitive dye specific for superoxide) as described previously 
(78). MitoTracker Green and MitoTracker Deep Red staining (79) 
was performed according to the manufacturer’s instructions. Intra-
cellular cytokine staining was performed as described previously 
(22). Isotype-matched Abs were used as control. Cells were acquired 
using a BD LSRFortessa flow cytometer (BD Biosciences), and data 
were analyzed using FlowJo software. Responder frequency and pro-
liferation capacity of donor CD4 and CD8 T cells were calculated as 
described previously (80).
T cell activation and PD-L1 staining. Total T cells were freshly 
obtained from Human Immunology Core (University of Pennsylvania) 
or thawed from cryopreserved samples. Cells were stimulated with 
Dynabeads Human T-Expander CD3/CD28 beads (Thermo Fisher) at 
a cell-to-bead ratio of 1:3 in culture medium. Beads were removed on 
day 3. Cells were harvested every 24 hours after stimulation for stain-
ing. Cells were stained with viability dye, washed, and stained with 
anti-CD4 (clone RPA-T4; BD Biosciences), anti-CD8 (clone RPA-T8; 
BD Biosciences), and either anti–PD-L1 (clone MIH1; eBioscience) 
or isotype control (mouse IgG1-κ, clone MOPC-21; BD Biosciences). 
Cells were then washed and acquired using a BD LSR II flow cytome-
ter, and data were analyzed using FlowJo.
PD-L1 expression on T cells during GVHD. Human PBMCs were 
collected from healthy volunteers (healthy control), and from 
patients after allogeneic BMT with or without GVHD at the time of 
collection (Supplemental Table 1). Cryopreserved cells were thawed, 
washed, and stained with LIVE/DEAD Aqua fixable viability dye 
(Invitrogen). Cells were washed and stained with the following Abs: 
anti-CD3 (clone UCHT1; BD Biosciences), anti-CD4 (clone RPA-T4; 
BD Biosciences), anti-CD8 (clone RPA-T8; BD Biosciences), anti-
CD14 (clone 61D3; eBioscience), anti-CD20 (clone 2H7; eBiosci-
ence), anti-CD28 (clone 28.2; BioLegend), anti-CD45RA (clone 
HI100; BioLegend), anti-CD45RO (clone UCHL-1; BD Biosciences), 
anti-CD95 (clone DX2; BD Bioscience), and anti-CD197 (clone 
3D12; BD Bioscience). Cells were also stained with either anti–PD-L1 
(clone 29E.2A3; BioLegend) or isotype control (mouse IgG2b, clone 
27-35; BD Biosciences). Cells were then washed and acquired using a 
BD LSRFortessa X-18 flow cytometer, and data were analyzed using 
FlowJo. The percentages of PD-L1+ cells were quantified for CD3+ 
CD14–CD20– and either CD4+ or CD8+ viable lymphocytes using the 
gating strategy shown in Supplemental Figure 2A.
Treg suppression assay. Tregs were isolated from LNs of WT B6 
or Pdl1–/– mice by magnetic-activated cell sorting column selection to 
more than 93% purity. Splenocytes isolated from B6 Ly5.2 mice were 
labeled with CFSE and used as responder cells. Responder cells were 
stimulated with purified anti-mCD3 mAb (0.25 μg/ml; eBioscience) 
and were cultured with or without freshly isolated Tregs at the indi-
cated T cell/Treg ratios. Cells were harvested on day 4, and prolifera-
tion was determined by CFSE dilution.
Histology. Representative mice were sacrificed on day 24 after BMT; 
harvested organs were processed and stored as described previously 
(81). Cryosections (6 μm) were fixed in acetone and stained with H&E, 
and histopathology scores were assigned as described previously (82).
FITC-dextran permeability assay. FITC-dextran assay was used 
to evaluate intestinal permeability as described previously (22). 
Briefly, mice were given 16 mg of FITC-dextran orally; 4 hours later, 
sion by activated donor T cells will provide new insight into the 
regulation of GVHD and suggest strategies to selectively inhibit 
PD-L1 on donor T cells that may be clinically useful to prevent 
GVHD, and may provide insights into a counterregulatory role of 
PD-L1 expression on activated T cells exposed to anti–PD-L1 mAb 
treatment for cancer.
Methods
Experimental animals. Female BALB/c (H-2d) mice were purchased 
from Charles River Laboratories. Female C57BL/6 (H-2b; termed B6), 
B10.BR (H-2k), Thy1.1 (H-2b) congenic, and Ifngr1–/– (H-2b) mice were 
purchased from The Jackson Laboratory. Female Ly5.2 (H-2b) con-
genic mice (CD45.1+) were purchased from National Cancer Institute 
Laboratory. B6-background Pdl1–/– and Pdl1–/– Pdl2–/– mice have been 
described previously (21, 76). BALB/c Thy1.1 congenic mice were 
obtained from Virginia L. Godfrey (University of North Carolina, 
Chapel Hill, North Carolina, USA).
Bone marrow transplantation. BMTs were performed as described 
previously (22). Briefly, recipient mice received total-body irradia-
tion at a lethal dose (BALB/c 700 cGy; B10.BR 1,000 cGy; B6 1,100 
cGy) by x-ray on day –1. BM cells alone or with purified T cells, CD25- 
depleted purified T cells, T cells plus Tregs, or splenocytes were infused 
i.v. on day 0. Mice were evaluated for evidence of clinical GVHD as 
described previously (77). Where indicated, irrelevant rat IgG (Rock-
land Immunochemicals Inc.) or anti–PD-L1 mAb (clone 10F.9G2) was 
administered i.p. at a dose of 200 μg on day 0 and day 3 after BMT.
Flow cytometry. The following unconjugated and fluorochrome- 
conjugated Abs were purchased from eBioscience: anti-CD4 (clone 
RM4-5), anti-CD8 (clone 53-6.7), anti–CD16/CD32 (clone 93), anti–
PD-L1 (clone MIH5), anti–PD-L2 (clone Ty25), anti-CD25 (clone 
PC61.5), anti-CD62L (clone MEL-14), anti-CD44 (clone IM7), anti–
LPAM-1 (clone DATK32), anti-CCR9 (clone CW-1.2), anti-CXCR3 
(clone CXCR3-173), anti–IFN-γ (clone XMG1.2), anti–TNF-α (clone 
MP6-XT22), anti–IL-6 (clone MP5-20F3), anti-CD45.1 (clone A20), 
anti-CD45.2 (clone 104), anti–Bcl-2 (clone 10C4), anti-CD127 (clone 
A7R34), anti-CD98 (clone RL388), anti-CD36 (clone 72-1), anti-
Foxp3 (clone FJK-16s), anti-Helios (clone 22F6), anti–CTLA-4 (clone 
UC10-4B9), anti–Lag-3 (clone C9B7W), anti–TIM-3 (clone RMT3-
23), anti–granzyme B (clone NGZB), anti-TIGIT (clone GIGD7), anti-
CD178 (clone MFL3), anti-CD90.1 (clone HIS51), and anti-CD90.2 
(clone 30-H12). 7-AAD (catalog 00-6993-50), annexin V (cata-
log 88-8006-74), and fixable viability dye (catalog 65-0865) were 
also purchased from eBioscience. Fluorochrome-conjugated anti– 
H-2Kb (clone AF6-88.5), anti–PD-1 (clone J43), anti–IL-17A (clone 
TC11-18H10), and anti–Ki-67 (clone B56) were purchased from BD 
Biosciences. Anti–Bcl-xL (clone 54H6)-AF488 and anti-Bim (clone 
C34C5) Abs were purchased from Cell Signaling Technology. Fluo-
rochrome-conjugated anti-CD304 (clone 3E12), anti-CD25 (clone 
PC61), anti-CD4 (clone RM4-5), and anti-CD8 (clone 53-6.7) were 
purchased from BioLegend. Anti-GLUT1 (catalog ab14683), anti-
CPT1a (clone 8F6AE9)-AF488, and anti-CPT2 (clone 1C2AE6) Abs 
were purchased from Abcam. Secondary Abs were purchased from 
Jackson ImmunoResearch. CFSE, CellTrace Violet, dihydroethidium 
(DHE), tetramethylrhodamine (TMRM; methyl ester), MitoTracker 
Green, MitoTracker Deep Red, and BoDipy (500/510 C1, C12) were 
purchased from Invitrogen–Molecular Probes. Cells were stained 
with viability dye to discriminate live from dead cells. Cell apoptosis 
The Journal of Clinical Investigation R e s e a R c h  a R t i c l e
2 6 5 8 jci.org   Volume 126   Number 7   July 2016
T cells were purified from spleen (5 spleens were pooled to make 1 
pooled sample and 3 pooled samples per group). Total RNA was 
extracted from purified T cells using the Qiagen RNeasy protocol. 
mRNA-sequence libraries were made according to the Illumina 
TruSeq protocol and run on 2 lanes of an Illumina HiSeq 2500 
sequencer with 1×50 single-end chemistry (at 6 samples per lane). 
Sequence data were processed and filtered as described previously 
by Cancer Genome Atlas (85). Bases and quality control (QC) assess-
ment of sequencing were generated by CASAVA 1.8. QC-passed reads 
were aligned to the NCBI build 37 (hg19) human reference genome 
using MapSplice (86). Aligned reads were sorted and indexed using 
SAMtools, and then translated to transcriptome coordinates and 
filtered for large inserts and zero mapping quality using UBU 1.0 
(https://github.com/mozack/ubu). For the reference transcriptome, 
UCSC hg19 knownGene was used (87), with genes located on non-
standard chromosomes removed. The abundance of transcripts was 
then estimated using an expectation-maximization algorithm imple-
mented in the software package RSEM (88) version 1.1.13. Estimated 
counts were normalized to the upper quartile (87) before comparison 
of expression across samples.
Differential gene expression analysis. RSEM-normalized expression 
levels were analyzed for differential expression using the software 
package SAM implemented in R (samr) (89, 90) with FDR calculated 
according to the method of Benjamini and Hochberg implemented in 
the samr package (91). Unsupervised hierarchical clustering was done 
and results plotted using the R function heatmap.2 in the gplots pack-
age (92), using the centroid clustering and Euclidean distance meth-
ods. Genes where differential expression was seen between WT and 
Pdl1–/– T cells at an FDR level of 0.20 are shown.
Pathway analysis. Pathway analysis was done using the QuSAGE 
software package implemented in R (35). CD4 and CD8 T cell data 
were pooled to yield 6 replicates per group (WT vs. Pdl1–/–). Gene sets 
tested in KEGG pathways with mouse homologs replacing human 
genes (those without a mouse homolog excluded from the mouse 
list) are included in Supplemental Table 2. Pathways with unadjusted 
P less than 0.05 associated with differential expression between WT 
and Pdl1–/– donor T cell samples are shown.
Lymphoma cell line and GVL studies. A20 is a BALB/c–derived lym-
phoma cell line that was modified to express luciferase (termed A20luc) 
as described previously (93). Lethally irradiated BALB/c recipients 
were infused with 107 T cell–depleted WT B6 BM cells alone or with 1 
× 106 WT B6 or Pdl1–/– purified T cells on day 0. To induce lymphoma, 
A20luc cells (3 × 105 or 1 × 106) were injected into mice by tail vein 
injection on day 0. Tumor growth was monitored weekly by luciferase 
imaging of lymphoma cells.
Statistics. Data were analyzed using GraphPad Prism (version 5 
or 6). Survival data were analyzed using log-rank test. For all other 
data, 2-tailed Student’s t test was used to analyze differences between 
groups. P less than 0.05 was considered as significant.
Study approval. Mice were bred and housed in a specific patho-
gen–free facility, and all studies were carried out under protocols 
approved by IACUC at the University of Minnesota. Peripheral blood 
samples from healthy donors and patients were obtained following 
written informed consent in accordance with the Declaration of Hel-
sinki. Samples were randomly selected from a cell bank for the study 
approved by the IRB at the University of Pennsylvania or Ohio State 
University, respectively.
plasma was collected, and fluorescence intensity of each sample 
was measured on a plate reader.
Colon lymphocyte isolation. Mice were sacrificed on day 24 after 
BMT, and colons were harvested, cut into pieces, and incubated 3–4 
times with 5 mM EDTA in RPMI 1640 with 10% serum at 37°C for 15 
minutes. Supernatants containing intraepithelial lymphocytes were 
discarded. Tissues were then incubated twice with 0.5 mg/ml and 
once with 1 mg/ml of Collagenase D (Roche) in RPMI 1640 with 10% 
serum at 37°C for 1 hour. Lymphocytes were isolated on a 40/80 Per-
coll (Sigma-Aldrich) gradient.
T cell activation. Purified T cells (purity ≥98%) from B6 Ly5.2 
mice and Pdl1–/– mice were cocultured in 96-well plates in the pres-
ence of plate-bound anti-mCD3 (coating density 5 μg/ml) and solu-
ble anti-mCD28 (1 μg/ml). Cells were harvested on day 4 and ana-
lyzed by flow cytometry.
Mixed lymphocyte reaction. DCs were generated as described pre-
viously (83). Briefly, BM cells isolated from BALB/c mice were cultured 
with recombinant mouse GM-CSF and recombinant mouse IL-4 for 7 
days. DCs were then irradiated (1,000 cGy) and used as stimulators. T 
cells purified from WT B6 or Pdl1–/– mice were labeled with CFSE and 
used as responder cells. Mixed lymphocyte reaction experiments were 
performed by coculturing of responder and stimulator cells at differ-
ent ratios in 96-well plates. Cells were harvested on day 5 and day 6, 
and T cell proliferation was determined by CFSE dilution.
Western blot analysis. Mice were sacrificed on day 5 or day 7 after 
BMT, and donor T cells were purified from spleen. Whole cell lysates 
were generated from unstimulated or pervanadate-stimulated T cells 
(84). Phosphorylated tyrosine (clone P-Tyr-100), phosphorylated 
Akt (clone D9E), phosphorylated PKC-θ (clone Thr538), total ZAP70 
(clone D1C10E), or β-actin (clone 8H10D10) was detected with pri-
mary mAb or polyclonal Ab (Cell Signaling Technology) followed 
by anti-mouse Ab conjugated with IRDye-800CW (LI-COR Biosci-
ences), anti-mouse Ab conjugated with Dylight-680 (Cell Signaling 
Technology), or anti-rabbit Ab conjugated with Dylight-800 (Cell 
Signaling Technology). Membranes were visualized with the Odyssey 
CLx scanner (LI-COR Biosciences).
Metabolism assays. Mice were sacrificed on day 4 after BMT, and 
donor T cells were purified from spleen (3 spleens were pooled to 
make 1 pooled sample and 4 pooled samples per group). ECAR and 
OCR of purified donor T cells were measured with an XF-24 Extracel-
lular Flux Analyzer (Seahorse Bioscience). Cells were seeded in a plate 
coated with Cell-Tak (BD Biosciences), and ECAR was measured in 
XF media with glutamine alone under basal condition and in response 
to glucose (10 mM), oligomycin (1 μM), and 2-deoxyglucose (50 mM). 
Also, cells were seeded in a Cell-Tak–coated plate, and OCR was mea-
sured in XF media (modified DMEM containing 25 mM glucose, 1× 
GlutaMAX (Gibco), and 1 mM sodium pyruvate) under basal condition 
and in response to oligomycin (1 μM), fluorocarbonyl cyanide phenyl-
hydrazone (0.3 μM), and antimycin A (2 μM). In selected experiments, 
OCR was also measured in the presence of etomoxir.
In separate experiments, purified donor T cells were cultured at 
37°C for 4 hours, culture supernatants were harvested, and glutamine 
consumption, glutamate production, and ammonium production 
were measured using a NovaFlex analyzer (Nova Biomedical). Culture 
medium without cells was used to normalize the NovaFlex data.
Illumina HiSeq sequencing and determination of individual gene 
expression levels. Mice were sacrificed on day 5 after BMT, and donor 
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